BOLT completed its purchase of Prana, but if the preferred shares and financing securities convert, earlier BOLT owners would hold 6.9% of the company. The filing excerpt gives no results showing that Prana's business would make up for this loss of ownership.
That shift gives former Prana owners and new investors most of the company. The filing excerpt does not describe Prana's business results or assets, so it gives no stated benefit to balance the smaller ownership share for BOLT's earlier owners.
Follow Bolt Biotherapeutics, Inc. (BOLT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BOLT